Transcranial Pulse Stimulation


The pioneering outpatient treatment option for neurodegenerative diseases

Shock Wave Therapy - Transcranial Pulse Stimulation (TPS) at RTL

RTL reports again about shock wave therapy TPS

On World Alzheimer’s Day, September 21, 2023, RTL has reported in several formats, including the main news “RTL AKTUELL” , about the shock wave therapy Transcranial Pulse Stimulation (TPS) as one of the most advanced and helpful treatment options for Alzheimer’s dementia.

In this article my colleague Prof. Dr. med. Ullrich Wüllner, director of the Neurocenter of the University Hospital Bonn (UBK) and one of his patients were interviewed. Prof. Wüllner also attests that Transcranial Pulse Stimulation (TPS) is an innovative shock wave method that not only stops Alzheimer’s disease, but can also bring about significant improvements in many patients.

I am pleased that TPS, which has long been considered one of the most promising therapeutic options for neurodegenerative diseases in specialist circles and at top international congresses, is also being presented more and more in the media. This is the only way that those affected and their relatives can even learn that we already have therapeutic methods at hand that can stop Alzheimer’s disease and significantly improve patients’ quality of life.

Prof. Dr. Musa Citak with TPS on RTL in the news

As an expert in regenerative medicine and a leading user of Transcranial Pulse Stimulation, Prof. Citak was the first physician to be featured on television. On November 22, 2021, RTL showed Prof. Citak with his patient Jochen Vieregge from Hamburg in the news program “RTL AKTUELL” as well as in other formats.

Today, in March 2023, that is 1 ½ years later, it is interesting to know: Alzheimer’s patient Jochen Vieregge continues to do as well as shown in the RTL report thanks to Transcranial Pulse Stimulation!

We will soon ask Jochen Vieregge and his wife for an interview again, so that the couple can personally report on the positive results of TPS and the resulting significant increase in quality of life for the benefit of other sufferers.

Transcranial Pulse Stimulation (TPS therapy) for Parkinson's disease

Clinically studied for over 15 years and now confirmed by the University of Vienna

In the course of the many years of research and development into the use of shock waves for neurophysiological diseases, which began back in the 1990s, Parkinson’s disease was one of the first indications to be researched and treated in a clinical setting using Transcranial Pulse Stimulation (TPS), which was still being developed at the time.

As a result, there has long been an encouraging and reliable body of data on Parkinson’s disease in particular – in some cases with long-term observations of patients who have been treated with TPS at regular intervals for over 12 years as part of clinical observation. Accordingly, a whole range of clinics and practices have long been treating patients with Parkinson’s with TPS – albeit still within the framework of so-called “off-label” therapy.

However, as the prevalence figures for Alzheimer’s dementia and other forms of dementia are much higher than for Parkinson’s, the number of studies on TPS logically concentrated initially on the Alzheimer’s indication. This is now being followed by Parkinson’s – and other indications such as depression, fatigue, autism and ADHD (attention deficit hyperactivity disorder).

Parkinson’s: science attests to the effectiveness and safety of TPS in equal measure

The Medical University of Vienna has been researching TPS for Parkinson’s disease for several years. In a first study publication on this indication, the Viennese researchers have now scientifically proven what has long been known to doctors working with TPS and many patients:

The results presented support and expand the understanding of the safety and efficacy profile of TPS in the treatment of neurodegenerative diseases such as Parkinson’s disease and TPS is attested to have a high potential for efficacy as an additional therapy. The disease status of the study subjects improved significantly and there were no clinically relevant side effects.

The scientists also consider the possible placebo effect to be unlikely in view of the clear patterns and frequency of motor improvements in the study (which is also the case in studies on other indications).

These study results, together with other clinical data, underline the potential of Transcranial Pulse Stimulation (TPS) to develop into a novel complementary neuromodulation therapy, according to the Viennese researchers.

Survey confirms study data: High efficacy attested

In a survey carried out last year at 11 clinics and practices on TPS for Parkinson’s, colleagues also came to the conclusion that such positive results urgently need to be followed up.

The result of the survey was that most of the 39 documented Parkinson’s patients treated with TPS showed clear improvements: 6 patients experienced very strong improvements, 18 strong improvements (including 11 with moderate and 5 with severe Parkinson’s) and 7 good improvements. No change was seen in only 6 cases, and in 2 the disease progressed despite treatment (note: these are remarkable and exceptional results in the field of therapy in general).

Overall, around 80% of patients benefited from TPS treatment, without any significant side effects. This underlines the effectiveness of TPS as a treatment option for Parkinson’s and the need for further research.

Further information on the first Parkinson’s study can be found here: LINK and the conditions under which we treat patients with Parkinson’s in practice can be found here: LINK.

We are delighted with these study results, which will now make it easier for patients with Parkinson’s to be treated effectively and safely with TPS.

Your Prof. Musa Citak, M.D.


Transcranial Pulse Stimulation (TPS) is a non-invasive, safe and outpatient treatment method that is very well tolerated. A TPS session takes only about 30 minutes in total and patients are not restricted in their daily life in any way before and after the treatment.


The patient sits relaxed in a treatment chair during therapy and can move freely at any time. The shock waves of the TPS have a targeted effect exclusively on the brain. Shaving the hair is not necessary, only a gel is applied to the head.


Low-energy shock wave pulses are hardly noticeable; you only hear the gentle click when the waves are delivered. In very rare cases, marginal side effects occur, such as a temporary mild headache, which quickly fades.

Transcranial Pulse Stimulation does not prevent degeneration, but it stimulates regeneration as the first treatment method. This is already a great progress, because: If we could stop any degeneration in advance, we would achieve eternal youth. But we are not there yet.
Prof. Musa Citak, M.D.
Prof. Dr. med. Musa Citak - Zitat

Below you can see our current TPS locations where Prof. Musa Citak, MD and his teams offer Transcranial Pulse Stimulation. For all locations, please feel free to contact the team at our Hamburg headquarters for questions, consultations, and appointments at or by phone at +49-(0)40-228 546 166

Nach oben